SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 16th, 2021 • Verve Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 14th day of January, 2021, by and among Verve Therapeutics, Inc. a Delaware corporation (f/k/a Endcadia, Inc.) (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
ENDCADIA, INC. (the “Company”)Stock Option Agreement • April 16th, 2021 • Verve Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Unless otherwise defined herein, the terms defined in the 2018 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED...Development and Option Agreement • April 16th, 2021 • Verve Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Development and Option Agreement (this “Agreement”), dated as of October 5, 2020 (the “Amendment Effective Date”), is made by and between Verve Therapeutics, Inc. a Delaware corporation (“Verve”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of Verve and Acuitas may be referred to herein as a “Party” or together as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. NON- EXCLUSIVE LICENSE...Non-Exclusive License Agreement • April 16th, 2021 • Verve Therapeutics, Inc. • Pharmaceutical preparations • New York
This Non-Exclusive License Agreement (“License Agreement”), dated as of October 14, 2020 (the “License Agreement Effective Date”), is made by and between Acuitas Therapeutics, Inc., a British Columbia corporation (“Acuitas”), and Verve Therapeutics, Inc., a Delaware corporation (“Verve”). Each of Acuitas and Verve may be referred to herein as a “Party” or together as the “Parties.”
SUBLEASESublease • April 16th, 2021 • Verve Therapeutics, Inc. • Pharmaceutical preparations
This SUBLEASE is made as of April 13, 2020, by and between FOGHORN THERAPEUTICS INC., a Delaware corporation having an address at 100 Binney Street, Suite 610, Cambridge, Massachusetts 02142 (“Sublandlord”) and VERVE THERAPEUTICS INC., a Delaware corporation having an address at 215 First Street, Suite 440, Cambridge, MA 02142 (“Subtenant”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND...Collaboration and License Agreement • April 16th, 2021 • Verve Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Collaboration and License Agreement (this “Agreement”) is effective as of April 3, 2019 (the “Effective Date”) and is entered into by and between Verve Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (“Verve”) and Beam Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware (“Beam”, collectively with Verve, the “Parties” and each, a “Party”).
